Palbociclib increases AML cell sensitivity to venetoclax and azacitidine by downregulating the antiapoptotic proteins MCL-1 and BCL-XL without affecting BCL-2 activity. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.